Rasi Breaks EMA's Silence on Glybera, Transparency Issues
By Cormac Sheridan
Wednesday, March 7, 2012
The month of May could prove to be an important milestone in the evolution of drug regulation in Europe. Around then, Amsterdam Molecular Therapeutics (AMT) Holding NV expects to hear a final decision from the European Medicines Agency (EMA) on its dossier for gene therapy treatment Glybera (alipogene tiparvovec), which has traced a highly circuitous route through various European Union institutions over the past couple of years.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.